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Objective: Lipoprotein (a) is an independent risk factor for atherosclerosis. Atherosclerotic degeneration is usually found
in abdominal aortic aneurysms (AAAs), whereas thoracic aortic aneurysms (TAAs) caused by aortic dissection are not
suggested to be linked pathogenetically to atherosclerosis. Lipoprotein (a) was analyzed in patients with AAA and TAA
and in healthy individuals in relation to the extent of atherosclerosis.
Methods: Included in the case control study were patients with AAA (n  75) and TAA with dissection (n  39) and
healthy control subjects (n 43), for a total of 157 participants. Serum lipoprotein (a) was measured with nephelometry.
Lipoprotein (a) levels were compared between age-matched and gender-matched paired samples of the three groups, and
an association of lipoprotein (a), aortic aneurysm, and the extent of atherosclerosis was determined in multivariate
analysis.
Results: Median lipoprotein (a) levels of patients with AAA and TAA and of control subjects were 18.9 mg/dL
(interquartile range [IQR], <9.6 to 40.5), less than 9.6 mg/dL (IQR, <9.6 to 16.7), and less than 9.6 mg/dL (IQR,
<9.6 to 16.3), respectively. Lipoprotein (a) was positively associated with the extent of atherosclerosis in patients and
control subjects (P < .0001). Lipoprotein (a) levels of patients with AAA were significantly higher compared with
patients with TAA (P < .0001) and control subjects (P < .0001). Multivariate analysis confirmed an independent
association between lipoprotein (a) and AAA (P .009). No significant differences of lipoprotein (a) were found between
patients with TAA and control subjects (P  .3).
Conclusion: The lipoprotein (a) serum level, an indicator of atherosclerosis, is significantly elevated in patients with
abdominal aneurysms independently of cardiovascular risk factors and the extent of atherosclerosis. Patients with TAAs
caused by dissection have lipoprotein (a) levels comparable with healthy individuals. (J Vasc Surg 2002;36:25-30.)
Aortic aneurysm and aortic dissection are characterized
as two distinct disease entities. Evidence from epidemio-
logic, experimental, and genetic investigations suggests
that the pathogenesis of abdominal aortic aneurysms
(AAAs) is related to atherosclerosis risk factors and athero-
sclerotic plaque formation.1-4 However, additional risk fac-
tors and potential alternative pathomechanisms for devel-
opment of abdominal aneurysms are discussed,5,6 and
particularly matrix metalloproteinases may play a pivotal
role in aneurysmal disease.7-11 In contrast, the initiation of
nontraumatic dissection of the thoracic aorta and subse-
quent aneurysmal dilation is not suggested to be linked
pathogenetically to the process of atherosclerosis.12-14
Lipoprotein (a) is a cholesterol-rich lipoprotein consist-
ing of one molecule of apolipoprotein B-100 linked to a
molecule of apolipoprotein (a) by a disulfide bridge.15
High plasma levels of lipoprotein (a) are strongly associated
with coronary artery disease, stroke, and peripheral artery
disease. Lipoprotein (a) thus was been established as an
independent risk factor and marker for atherosclerosis.16-21
Lipoprotein (a) has a high affinity for proteoglycans, which
is probably why it is found in high amounts in atheroscle-
rotic plaques of the human aorta.22,23 Elevated serum levels
of lipoprotein (a) have been reported in small patient series
with AAAs.23,24 However, no data on lipoprotein (a) values
of patients with thoracic aortic aneurysms (TAAs) or dis-
section have been published to date, and whether lipopro-
tein (a) is coincidentally elevated in patients with AAAs
because of concomitant atherosclerotic comorbidities or
independently indicates an increased risk for aneurysm
formation is unknown. Elevated levels of lipoprotein (a)
cause endothelial and intimal damage and thus may in-
crease the susceptibility for intimal injury and initiation of
aneurysm formation. Because TAAs from aortic dissection
and atherosclerotic abdominal aneurysms are considered as
two distinct disease entities, differences in lipoprotein (a)
serum levels may be expected between these groups.
The aim of this study was to investigate lipoprotein (a)
serum levels in patients with atherosclerotic AAAs and
TAAs caused by aortic dissection and in healthy individuals.
We hypothesized that abdominal aneurysms are associated
with increased lipoprotein (a) serum levels because athero-
sclerosis may be involved. Patients with TAA with dissec-
tion were expected to have lipoprotein (a) levels similar to
healthy control subjects because atherosclerosis is not sug-
gested to play a pathogenetic role for this disease.
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METHODS
Study design. The study was designed as a case
control study. We prospectively included 75 consecutive
patients with AAA, 39 consecutive patients with TAA dis-
section and aneurysmal dilation, and 43 healthy individuals
without aortic aneurysms, without any atherothrombotic
risk factor, and without a history of atherosclerotic disease.
The study was performed according to the Declaration of
Helsinki. All patients gave their written informed consent.
Patients. Consecutive patients with TAAs or AAAs
admitted from January 1 to December 31, 2000, to the
Department of Emergency Medicine and the Department
of Angiology of a tertiary care university hospital were
eligible for the study. Patients with inflammatory aortic
aneurysms25 (n  2) and luetic aortic aneurysms (n  0)
were excluded. Inflammatory aneurysms were diagnosed
with computed tomographic (CT) scan in conjunction
with surgical findings (n  2), and luetic aortic aneurysms
were excluded with clinical history, routine serologic tests,
and CT scans. One patient with penetrating atherosclerotic
aortic ulcer26,27 with diagnosis during a surgical procedure
also was excluded. Patients with hereditary defects of con-
nective tissue, like Marfan’s syndrome, were not eligible for
the study (n  3). Patients with thoracic aortic dissection
were only eligible when aneurysmal dilation was coinciden-
tally present. Patients with traumatic aneurysms or dissec-
tion were not eligible for the study. Healthy individuals
without aortic aneurysm, without atherothrombotic risk
factor (diabetes mellitus, smoking, arterial hypertension,
hyperlipidemia), and without medical history and clinical
signs of atherosclerotic disease were recruited at the outpa-
tient ward of the emergency department within the same
time interval.
Definitions. An aneurysm was defined as a permanent
dilatation of the aorta, with a diameter of at least 50%
greater than the proximal neck.28 The diagnosis was estab-
lished with color-coded duplex sonography, transthoracic
and transoesophageal echocardiography, and CT scan. Sur-
gery and autopsy reports and angiographic findings were
used to confirm data from the clinical investigation. All
diseases were confirmed with a combination of at least two
independent examinations: the diagnosis of AAA was set-
tled in 42 patients with CT scan plus surgery (additional
angiography in 32 of these patients), in 30 patients with CT
scan in conjunction with angiography, and in three patients
with autopsy. The diagnosis of TAA and dissection was
made in 18 patients with CT scan plus surgery, in two
patients with echocardiography plus surgery, in 15 patients
with combination of CT scan, echocardiography, and an-
giography, and in four patients with autopsy. All radio-
graphic procedures were performed and evaluated by inde-
pendent radiologists. Diabetes mellitus was defined as
fasting blood glucose levels of more than 110 mg/dL
measured three times and pathologic oral glucose tolerance
tests and hemoglobin A1c (glycosylated hemoglobin) more
than 6.5 mg/dL. Hyperlipidemia was defined as fasting
total serum cholesterol level more than 200 mg/dL, low
density lipoprotein cholesterol level more than 130 mg/
dL, or serum triglyceride level more than 180 mg/dL and
all patients on lipid-lowering medication. Arterial hyperten-
sion was diagnosed according to the World Health Organi-
zation criteria.29 Patients who were smoking more than
three cigarettes per day were regarded as current smokers.
The diagnosis of cerebrovascular atherosclerotic disease
(CVD) of the extracranial carotid artery was assessed with
duplex sonography and confirmed with angiography. Pe-
ripheral artery disease (PAD) was evaluated clinically, with
ankle brachial index measurements, duplex sonography,
and peripheral angiography in selected cases. Coronary
artery disease (CAD) was diagnosed with clinical history, in
conjunction with treadmill exercise testing, myocardium
scintigraphy, and coronary angiography in selected pa-
tients. Patients were grouped according to the extent of
atherosclerotic disease into atherosclerosis in one vessel
area (CVD, or PAD, or CAD), into atherosclerotic disease
in two vessel areas, or into generalized atherosclerosis in
three vessel areas (concomitant CVD, CAD, and PAD).
Blood samples. Antecubital venous blood samples
were collected at initial presentation of the patient at the
emergency department or at the outpatient ward of the
angiology department. Samples were centrifuged immedi-
ately and then frozen at 80°C until use. In previous
experiments, we ascertained that freezing once did not
affect the assay performed.15 Serum lipoprotein (a) was
measured with nephelometry on a Behring Nephelometer
Analyzer II with the N Latex Lipoprotein (a) reagent
Table I. Clinical characteristics of patients with AAA and TAA with aortic dissection and healthy control subjects
AAA
(n  75)
TAA
(n  39)
Control subjects
(n  43) P value
Age (years; median, IQR) 72 (66 to 78) 64 (56 to 74) 70 (59 to 76) .01
Male gender 61% (81%) 25% (64%) 30% (70%) .2
Arterial hypertension 42% (65%) 29% (74%) 0 .0001
Hyperlipidemia 50% (67%) 6% (15%) 0 .0001
Smoking 33% (44%) 11% (28%) 0 .0001
Diabetes mellitus 15% (20%) 1% (3%) 0 .0001
Cerebrovascular disease 57% (76%) 12% (31%) 0 .0001
CAD 39% (52%) 8% (21%) 0 .0001
PAD 39% (52%) 5% (13%) 0 .0001
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(Dade Behring, Marburg, Germany), according to the
manufacturers instructions. The lower detection level of
the used method was less than 9.6 mg/dL, and the coeffi-
cient of variation was 2.1%.
Statistical analysis. Continuous data are presented as
the median and the interquartile range (IQR; range from
the 25th to the 75th percentile). Percentages were deter-
mined for dichotomous variables. The Kruskal-Wallis test
was used to compare lipoprotein (a) serum levels of patients
with thoracic and AAAs and healthy control subjects over-
all. Patients of the three groups then were individually
matched. Matching was performed blinded with respect to
patient data. A difference of less than 5 years was accepted
for matching patient age. The Wilcoxon paired rank test
was applied to compare continuous variables of age-
matched and gender-matched patients. A multivariate lo-
gistic regression model was applied to assess the indepen-
dent association of lipoprotein (a) serum levels and AAAs
compared with TAAs. Results of the logistic regression
model are given as the odds ratio and the 95% confidence
interval. The Hosmer-Lemeshow test was used to assess the
model fit. All P values are two-sided. A P value of less than
.05 was considered as statistically significant. Calculations
were performed with MS Excel for Windows 2000 and
SPSS (Version 10.0, SPSS Inc, Chicago, Ill) for Windows.
RESULTS
Overall, 157 individuals were included in the study: 75
patients with AAA, 39 patients with TAA, and 43 healthy
control subjects. Clinical characteristics of patients and
control subjects are given in the Table. Patients with AAA
exhibited the highest cumulative frequency of atheroscle-
rotic risk factors and atherosclerotic comorbidities, except
for arterial hypertension, which was found most frequently
in patients with TAA. All women included in this analysis
were postmenopausal. Sixteen patients (21%) with AAA
had a coincident abdominal aortic dissection. In all 39
patients with TAA, presence of dissection was confirmed, in
26 patients (67%) in the ascending aorta and in 13 patients
(33%) in the descending aorta.
The median lipoprotein (a) level of patients with AAA
was 18.9 mg/dL (IQR, 9.6 to 40.5), in patients with
TAA less than 9.6 mg/dL (IQR, 9.6 to 16.7), and in
healthy individuals less than 9.6 mg/dL (IQR, 9.6 to
16.3; Fig 1). Overall, patients with AAA had significantly
higher lipoprotein (a) serum levels compared with patients
with TAA and healthy individuals (Kruskal-Wallis, P 
.0001). No significant differences of lipoprotein (a) serum
levels were found between patients with (n  16) and
without (n 59) dissection of AAAs (P .7) and between
patients with dissection of the ascending (n  26) and
descending (n  13) thoracic aorta (P  .5).
Lipoprotein (a) serum levels in the sample of 157
individuals were significantly associated with the extent of
atherosclerosis as indicated by the number of affected vessel
areas (P .0001). Patients with more extensive atheroscle-
rotic disease had the highest lipoprotein (a) serum levels,
and healthy subjects had the lowest lipoprotein (a) serum
levels. Consistent findings were observed in patients with
AAA (P  .0001) and TAA (P  .003; Fig 2).
Furthermore, age-matched and gender-matched
paired samples of patients with AAA and TAA and control
subjects were analyzed with respect to differences of li-
poprotein (a) levels. No significant differences of age and
gender were found between these groups of paired samples.
Patients with AAA had significantly higher lipoprotein (a)
levels compared with age-matched and gender-matched
patients with TAA (38 matches; median, 27.5 mg/dL;
IQR, 14.4 to 54.7; versus median, 9.6 mg/dL; IQR,
9.6 to 16.9; Wilcoxon, P  .0001) and compared with
healthy individuals (41 matches; median, 31.7 mg/dL;
IQR, 16.6 to 61.9; versus median, 9.6 mg/dL; IQR,
9.6 to 17.7; Wilcoxon, P .0001). No significant differ-
ences were observed between patients with TAA and
healthy individuals (35 matches; median, 9.6 mg/dL;
IQR, 9.6 to 13.8; versus median, 9.6 mg/dL; IQR,
9.6 to 17.7; Wilcoxon, P  .3). Stratified analysis was
performed to adjust for patient gender. In both strata, male
and female, patients with AAA had higher serum levels of
lipoprotein (a) compared with patients with TAA (P .009
and P  .02, respectively) and compared with healthy
subjects (P  .0001 and P  .01, respectively). Patients
with TAA had similar lipoprotein (a) levels compared with
healthy subjects in the male and female stratum (P .5 and
P  .3, respectively).
A multivariate logistic regression model was applied to
assess the independent association of AAAs and lipoprotein
(a) serum levels in the groups of patients with AAA and
TAA. Patient age, gender, arterial hypertension, smoking,
hyperlipidemia, diabetes mellitus, and extent of atheroscle-
rosis (number of affected vessel areas) were entered into the
Fig 1. Serum levels of lipoprotein (a) in patients with AAA (n 
75) and thoracic aortic disease (n  39) and healthy control
subjects (n 43). Box plots indicate median, IQR (range from 25th
to 75th percentile), and range.
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model as possible confounding variables. Healthy control
subjects were not included in this model because of the
collinearity between the group classification and these pos-
sible confounding variables. Multivariate analysis con-
firmed an independent association between lipoprotein (a)
and AAA: patients with higher lipoprotein (a) serum levels
had a significantly increased risk for having an AAA (odds
ratio, 1.1; 95% confidence interval, 1.0 to 1.1; P  .009).
The final model had an acceptable fit (C  4.0, df  8,
P  .9).
DISCUSSION
We found that patients with AAAs had significantly
elevated lipoprotein (a) serum levels, whereas patients with
thoracic aortic disease had lipoprotein (a) serum levels
comparable with healthy individuals. The association be-
tween lipoprotein (a) and AAA was independent of athero-
sclerotic risk factors and the extent of atherosclerosis, al-
though lipoprotein (a) serum levels were significantly
associated with atherosclerosis in patients and control sub-
jects.
The physiologic role of lipoprotein (a) has not been
entirely determined yet. One of the main sites of catabolism
is the kidney. We could recently show that fragments of
lipoprotein (a) were excreted via the urine and that de-
creased kidney function led to an accumulation of these
apo(a) fragments in the plasma and to increased plasma
lipoprotein (a) levels.30-34 It also has been speculated that
lipoprotein (a) is involved both in tissue synthesis and tissue
repair. In patients with aortic aneurysms, it was suggested
to play a role in thrombus formation and reinforcement of
the aortic wall,23 which might explain it’s elevation, partic-
ularly in patients with abdominal aneurysms where mural
thrombus formation frequently occurs. However, lipopro-
tein (a) elevation also was found in patients with intracra-
nial aneurysms without clinically significant atheromatous
disease.35,36
Lipoprotein (a) values of patients with AAAs in this
patient series compare well with previous findings.24 How-
ever, Fig 1 shows a rather wide variability of lipoprotein (a)
values in the group of patients with AAA. The extent of
concomitant atherosclerosis seems to be the major deter-
minant for this variability (Fig 2). The predictive value of
lipoprotein (a) has not been determined yet, although Watt
et al37 reported that elevated plasma levels of lipoprotein
(a) were not a risk factor for aneurysm rupture. Further
longitudinal observations will be necessary to investigate
whether excessively high lipoprotein (a) values are of prog-
nostic importance.
Lipoprotein (a) has repetitively been shown to be asso-
ciated with the presence of clinically significant atheroscle-
rosis in the coronary, peripheral, and cerebral vessels.16-21
We believe our study to be the first demonstration that
patients with more extensive atherosclerotic disease indi-
cated by the number of affected vessel areas exhibit the
highest lipoprotein (a) levels, whereas healthy individuals
free of atherosclerosis had the lowest lipoprotein (a) values.
Because several risk factors for atherosclerosis and abdom-
inal aneurysms are identical, an association between li-
poprotein (a) and AAA has already been assumed previous-
ly.38 Lipoprotein (a) is significantly associated with the
extent of atherosclerosis, and patients with AAA are likely
to have several atherosclerotic comorbidities. Therefore,
higher lipoprotein (a) values in patients with AAA may be
explained by a high prevalence of concomitant atheroscle-
rosis. However, the findings of the multivariate analysis
suggest that these lipoprotein abnormalities are associated
with the pathophysiology of abdominal aneurysms inde-
pendently of cardiovascular risk factors and atherosclerosis.
Atherosclerosis per se is not the exclusive explanation
for the development of AAAs.5,6,39 It is widely recognized
that a chronic transmural vascular inflammatory process
and destruction of connective tissue proteins within the
outer aortic wall play a role in the initiation and progression
of aortic disease.40-44 The development of aneurysmal di-
latation is attributed to the depletion of medial and adven-
titial elastin, whereas rupture of the aneurysm is generally
thought to involve the additional degradation of adventitial
collagen. In particular, matrix metalloproteinases, zinc-
dependent enzymes that are capable of degrading collagen,
Fig 2. Serum levels of lipoprotein (a) according to extent of atherosclerotic disease in subgroups of patients with AAA
(n  75) and thoracic aortic disease (n  39) and healthy control subjects (n  43). Box plots indicate median, IQR
(range from 25th to 75th percentile), and range.
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elastin, and gelatin, have been detected in aortic aneurys-
mal tissue and evaluated in their role in aneurysmal devel-
opment by several recent studies7-11: metalloproteinase 2
and metalloproteinase 9 have been identified in increased
levels within aortic aneurysm and may be responsible for
aneurysm formation and expansion. It may be worth exam-
ining whether lipoprotein (a), which causes endothelial
dysfunction and intimal damage, facilitates or contributes
to the vascular inflammatory process of aneurysm forma-
tion.
In this study, lipoprotein (a) was significantly elevated
in patients with abdominal aortic disease, whereas patients
with TAAs caused by dissection had lipoprotein (a) serum
levels similar to healthy individuals. We have included only
patients with TAA caused by dissection on purpose because
in these patients the cause for aneurysmal dilation seems to
be the weakening of the wall by the dissecting membrane
and atherosclerosis as a potential cause can be widely ex-
cluded. Therefore, these patients seemed to be a homoge-
nous comparison group. Different patterns of atheroscle-
rosis, various hemodynamic factors, and intrinsic anatomic
differences of the proximal and distal aorta contribute to
the development and progression of aortic aneurysms in the
thoracic and abdominal part of the vessel.45,46 Our findings
suggest that lipoprotein (a), a marker for atherosclerosis
risk, is not associated with the development of TAAs caused
by dissection. In these patients, processes other than li-
poprotein abnormalities and atherosclerosis initiate aortic
dissection, which subsequently leads to aneurysmal dila-
tion. On the other hand, in patients with abdominal aneu-
rysms, no differences of lipoprotein (a) were found in
patients with and without dissecting membrane. Dissection
of the abdominal aorta may occur as a complication of the
aneurysmal process rather than the cause for initiation of
aortic dilation.
It is known that lipoprotein (a) levels vary during and
after menopause. However, all women in this study were
postmenopausal, and therefore, we cannot comment on
this issue.
The case control study design implies some limitations;
in particular, a causal relationship between lipoprotein (a)
and AAA cannot be proven from these data. This issue has
to be addressed in longitudinal studies, which include large
numbers of subjects without AAA, follow the subjects, and
determine whether elevated lipoprotein (a) is predictive of
the development of AAA.
CONCLUSION
Lipoprotein (a) serum level, an indicator of atheroscle-
rosis, is significantly elevated in patients with abdominal
aneurysms independently of cardiovascular risk factors and
the extent of atherosclerosis. Elevated lipoprotein (a) thus
may be a risk factor for AAA. Patients with TAAs with
dissection have lipoprotein (a) levels comparable with
healthy individuals.
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